The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced MSS rectal cancer.

Trial Details

NCT ID
NCT06254521
Phase
PHASE2
Sponsor
First Affiliated Hospital of Guangxi Medical University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Tislelizumab combined with chemotherapy
Locations (sample)
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Age ≥18 years old and ≤70 years old.
  • Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemi…
  • The lower edge of the tumor is less than 12cm from the anus as measured by colonoscopy and MRI,or TRUS.
  • It was confirmed by magnetic resonance imaging (MRI) or intracavitary ultrasound of the rectum as T3-4 or N+, and M0 by enhanced CT.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →